Shares of Biomea Fusion, Inc. (Nasdaq: BMEA) surged to $32.87 during early trading on Monday, driven by positive clinical data from its Phase II study on BMF-219 in type 2 diabetes patients. However, by the end of the trading session, $BMEA closed at $24.42, reflecting a decline of $6.25 (20.39%).

Despite the decline in $BMEA, Biomea Fusion received positive assessments from various investment firms. Piper Sandler maintained an "Overweight" rating and raised the price target from $40 to $45. HC Wainwright & Co. also maintained a "Buy" rating and increased the price target from $37 to $50. JP Morgan held an "Overweight" rating and raised the price target from $38 to $51. On the other hand, Citigroup maintained a "Buy" rating and significantly raised the price target from $53 to $90.

In other news, Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) has scheduled a webcast and conference call for tomorrow (Tuesday, June 27, 2023) at 8:00 a.m. (ET) to present the top-line results from the Phase 2 clinical trial of ADX-629 in patients with chronic cough.

In after-hours, $ALDX was trading at $7.85, experiencing a positive gain of $0.34 (4.55%), in anticipation of tomorrow's expected clinical trial outcomes.

Additionally, Nkarta, Inc. (Nasdaq: NKTX) also plans to hold a conference call tomorrow at 8:00 a.m. ET to provide an overview of the updated clinical data from the ongoing clinical trial of NKX101, the company's allogeneic, off-the-shelf CAR NK cell therapy candidate designed to target NKG2D ligands on cancer cells.

On Monday, $NKTX closed at $4.53, down $0.09 (1.95%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)